Tirzepatide and Stomach Emptying in Adults With Type 1 Diabetes and Excess Weight
Tests how tirzepatide affects stomach emptying in adults with type 1 diabetes and overweight.
Plain-language title generated from the registry record
Registry title: A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Key facts
- Where
- Miami, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07803744, who can take part
Where in United States
- Clinical Pharmacology of MiamiMiami, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07803744
- Record updated
- 23 September 2026
- Original description
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.Read full original descriptionShow less
A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
Participation in this study will last about 8 weeks, including screening and follow-up.
Inclusion: Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening; Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening; Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening.
Exclusion: Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery; Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists; Participants who have a known clinically significant gastric emptying abnormality.